Skip to main content
Premium Trial:

Request an Annual Quote

Christian Lajoux, Emad Khalil, Elizabeth Tallett, George Zavoico

French Pharmaceutical Group Reappoints Sanofi-Aventis France President to Run Board
Christian Lajoux, president of Sanofi-Aventis France, has been reappointed as board president of France’s pharmaceutical industry group, Les Entreprises du Médicament – LEEM. Lajoux’s term, set to expire at the end of 2008, will instead be extended through 2010.
Dans un contexte de fragilisation de l’industrie pharmaceutique, le Conseil d’Administration du Leem confie à Christian Lajoux la mission de porter jusqu’en 2010 un projet d’adaptation au coeur des sciences du vivant et au service du progrès thérapeutique en France.
The reappointment, made by the group’s board of directors, is subject to ratification by the General Assembly of LEEM on June 13. Lajoux was first elected to head LEEM’s board in July 2006.
Among Lajoux’s priorities in his new term, according to a statement issued by LEEM, will be updating the industry’s plan for surmounting fiscal and regulatory hurdles that threaten to eliminate about 32,000 French pharma industry jobs by 2015 [see Around the Regions, this issue].

Lawyer for Biotech Funds Joins Law Firm’s New Singapore Office
Emad Khalil has joined the law firm of Gibson Dunn and Crutcher, where he will specialize in corporate transactions, including mergers and acquisitions, private equity, capital markets, banking and finance. He is based at the firm’s new Singapore office.
Khalil joined Gibson Dunn and Crutcher from Jones Day, where he headed that law firm’s Global Projects Practice. He has represented life sciences investors, including Altus, Bio*1 Fund, and the Biomedical Sciences Investment Fund.
Fluent in Arabic, Khalil has also represented major companies throughout Asia, Middle East, and the US in energy and infrastructure projects, and has served as a principal adviser to Jordan on developing and enacting modern securities legislation.
Earlier, Khalil was a co-founding partner of the New York practice of Afridi and Angell, where he spent significant time working from that firm's Dubai and Abu Dhabi offices; and practiced with Cravath, Swaine and Moore in New York.
Khalil, who is admitted to practice in New York, received his JD degree from Harvard University in 1990.

Life Sciences Management Consultancy Principal Named to Meredith Board
Elizabeth Tallett, a principal of Hunter Partners, a management company for early- to mid-stage pharmaceutical, biotech and medical device companies, has been appointed to the board of directors of the Meredith Corporation, effective with the August 2008 meeting. Three months later, Tallett will stand for election as a Class I director at the company's annual shareholders meeting.
Tallett previously served as president and CEO of Transcell Technologies, as president of Centocor Pharmaceuticals, as a member of the Parke-Davis executive committee; and as director of worldwide strategic planning for Warner-Lambert, which was acquired in 2000 by Pfizer.
Born and educated in the UK, Tallett graduated from Nottingham University with dual first class honors degrees in mathematics and economics. She is a member of the boards of Principal Financial Group, Varian, Coventry Health Care, and IntegraMed America.
Meredith is a publicly traded, $1.6 billion-a-year media giant headquartered in Des Moines, Iowa. The company owns several local TV stations as well as magazines that include Better Homes and Gardens, Parents, Ladies' Home Journal, and Family Circle.

Cantor Fitzgerald US Equity Analyst Honored for Earnings Estimates
George Zavoico, a member of Cantor Fitzgerald’s US equity research team, has been recognized for excellence in the first annual Financial Times/StarMine awards. Zavoico was awarded the number one spot in the “Top Earnings Estimators by Industry – US” category for his research in the biotechnology sector.
Zavoico joined Cantor Fitzgerald in 2006. Previously, he was a founder and president of Cronamere Consulting Group, a biotechnology and pharmaceutical industry consulting and medical writing and media company. He established CCG in 1997 and specialized in competitive drug research and marketing assessment, medical communications for the industry and general public, due diligence studies for investment banking, and consulting on regulatory affairs issues, including the writing and preparation of clinical trial reports.
Before forming CCG, Zavoico held senior research program positions at Bristol-Myers Squibb, Alexion Pharmaceuticals, and T Cell Sciences.
Zavoico received a BSci degree in biology from St. Lawrence University in 1974, and a doctorate degree in physiology from the University of Virginia in 1981. He held post-doctoral positions at the University of Connecticut Health Center and at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.